Cyclic Nucleotide Phosphodiesterases, Type 4
"Cyclic Nucleotide Phosphodiesterases, Type 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic nucleotide phosphodiesterase subfamily that is found predominantly in inflammatory cells and may play a role in the regulation of CELL-MEDIATED IMMUNITY. The enzyme family includes over twenty different variants that occur due to multiple ALTERNATIVE SPLICING of the mRNA of at least four different genes.
| Descriptor ID |
D054703
|
| MeSH Number(s) |
D08.811.277.352.640.150.400 D12.644.360.008.400 D12.776.476.008.400
|
| Concept/Terms |
Cyclic Nucleotide Phosphodiesterases, Type 4- Cyclic Nucleotide Phosphodiesterases, Type 4
- Phosphodiesterase-4
- Phosphodiesterase IV
- PDE4 Phosphodiesterases
- Phosphodiesterases, PDE4
- Cyclic Nucleotide Phosphodiesterase PDE4 Family
- Phosphodiesterase 4
- Type 4 Cyclic Nucleotide Phosphodiesterase
|
Below are MeSH descriptors whose meaning is more general than "Cyclic Nucleotide Phosphodiesterases, Type 4".
Below are MeSH descriptors whose meaning is more specific than "Cyclic Nucleotide Phosphodiesterases, Type 4".
This graph shows the total number of publications written about "Cyclic Nucleotide Phosphodiesterases, Type 4" by people in this website by year, and whether "Cyclic Nucleotide Phosphodiesterases, Type 4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclic Nucleotide Phosphodiesterases, Type 4" by people in Profiles.
-
Human muscle-specific A-kinase anchoring protein polymorphisms modulate the susceptibility to cardiovascular diseases by altering cAMP/PKA signaling. Am J Physiol Heart Circ Physiol. 2018 07 01; 315(1):H109-H121.
-
Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer. Clin Cancer Res. 2018 04 15; 24(8):1987-2001.
-
Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018 03; 78(3 Suppl 1):S43-S52.
-
PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S67-73.
-
Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11/LKB1-driven regulation of cAMP phosphodiesterase-4D. Mol Cancer Ther. 2014 Oct; 13(10):2463-73.
-
Protein kinase A and phosphodiesterase-4D3 binding to coding polymorphisms of cardiac muscle anchoring protein (mAKAP). J Mol Biol. 2013 Sep 23; 425(18):3277-88.
-
Identification of novel mutations confirms PDE4D as a major gene causing acrodysostosis. Hum Mutat. 2013 Jan; 34(1):97-102.
-
Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res. 2010 Jul 15; 70(14):5717-27.
-
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res. 2008 Dec 01; 14(23):7717-25.
-
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell. 2005 Oct 07; 123(1):25-35.